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1.0 Chapter One: Introduction 
The deliberate inhalation of volatile substances with the intention of intoxication is one of 
the most under-appreciated and under-researched substance abuse concerns in the world (Cruz, 
2011; Cruz and Bowen, 2008; Howard et al., 2011). This is despite the highly dangerous and 
volatile nature of solvents, and the risk of serious neurological harm or death that can result from 
such abuse (Bowen, et al., 1999; Butland et al., 2012). The scientific study of inhalant abuse is 
complicated by the diverse chemical nature of inhalants, which comprise several distinct chemical 
groups (see Table 1) with numerous different molecular structures (see Bowen and Cruz, 2014 for 
a review). The aromatic hydrocarbon toluene (methylbenzene), found in a variety of household 
and industrial products, is one of the most ubiquitous substances with thousands of industrial and 
commercial products containing some level of this solvent (Hass, 1999) including airplane glue, 
gasoline, paint thinner, spray paint, and sealant. Estimates of toluene production per year are in 
the millions of tons, with upwards of a third of that amount being used in commercial products 
(IARC, 1989; ATSDR, 2000). 
1.1 Inhalants 
Inhalants are comprised of an extensive category of abused compounds. This group is 
comprised of compounds that are volatile at room temperature. It should be noted therefore that 
drugs which are inhaled but are not volatile at room temperature (e.g., cocaine, tobacco, marihuana, 
etc.) are not considered to be inhalants. Many substances can be included in this definition of 
inhalants and, as such, several classification schemes can be used. If we classify inhalants based 
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on the commercial products that contain them, we can distinguish categories such as adhesives, 
aerosols, cleaning agents, solvents and odorizers, among others. 
Table 1. Commonly misused inhalants. Adapted from Bowen and Cruz (2012). 
Group Characteristics Effects Commercial 
Products 
Alkyl-nitrites A nitrite group Vasodilation, smooth 
muscle relaxation  
“Poppers” 
Room Odorizers 
Nitrous Oxide Inorganic anesthetic 
gas / propellant  
CNS depression, hilarity, 
analgesia, anesthesia  
Whipped dairy 
cream chargers, 
nitrous oxide tanks 
Other 
Anesthetics 
Gases or volatile 
liquids 
Relaxation, numbness 
analgesia, anesthesia, 
respiratory depression 
Anesthesia bottles 
(ether, Halothane®, 
Isoflurane®, 
Desflurane®) 
Propellants-fuels Flammable gases that 
are liquefied under 
pressure 
Relaxation, hallucinations, 
illusions 
Cigarette lighters, 
cooking fuels, 
hairsprays, central 
air conditioning 
units 
Solvents Liquids that dissolve 
other substances 
without any change 
in chemical 
composition 
Initial disinhibition 
followed by a more 
prolonged depression. 
Illusions, hallucinations. 
Paints, paint 
thinners, glues, 
inks, lacquers, 
varnish removers, 
degreaser agents, 
spot removers, 
motor fuels 
 
Solvents (e.g., toluene) as a class of chemicals are especially noted for their high level of 
solubility. The high lipid solubility displayed by solvents results in these compounds easily 
absorbing into bodily tissues. Toluene, for example, is absorbed efficiently by lung, fat, and brain 
tissue and in high concentrations is known to produce “intoxication” (Cruz, 2011). Given how 
widely available and cheap products containing toluene are it is no surprise that toluene-based 
inhalants are prime targets for recreational misuse.  
1.2. Epidemiology of Inhalant Abuse 
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The abuse of volatile substances, such as toluene, is a worldwide phenomenon of 
considerable importance (Dell et al., 2011; Medina-Mora and Real, 2008). According to 
SAMHSA’s National Survey on Drug Use and Health, it has been estimated that, among United 
States residents over the age of 12, 8% admit to deliberately misusing an inhalant at least once, 
and of those individuals who began using illicit drugs for the first time within the past month, 7.5% 
chose to abuse inhalants (SAMHSA, 2012). Furthermore, in 2011 inhalants were the fifth most 
initiated illicit drug amongst United States residents over the age of 12, ahead of both cocaine and 
heroin (SAMHSA, 2012). Inhalant abuse is very common among adolescents and pre-adolescents 
with 14.9% of eighth graders admitting to having deliberately inhaled something in order to get 
high at least once in their lives.  This places inhalant abuse as the second most commonly abused 
substance in this age group behind cannabis inhalation (Bowen 2011).  
The problem of inhalant abuse begins early. According to the results of the 2007 
Monitoring the Future National Survey, over half of students who admit to misusing an inhalant 
did so for the first time by the end of their first year in high school (Johnston, et al., 2007). 
However, evidence from the same survey suggests that, of high school individuals who admit to 
misusing an inhalant, half had not done so in the past year. Thus, individuals who experiment with 
inhalant misuse at a young age generally do not continue to regularly abuse the compound. 
However, it is also possible that abuse continues and the children simply drop out of school. The 
number of users is estimated to increase at a rate exceeding three-quarters of a million individuals 
every year (Howard et al., 2011). Evidence also suggests, that among high school students, the 
perception that inhalant abuse is harmful is decreasing (Williams and Storck, 2007), which is an 
indicator of the risk for future increases in inhalant abuse amongst high school students.  
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Initially, research suggested that inhalant misuse (toluene misuse in particular) was more 
likely among adolescent boys than girls. However, recent survey data has suggested that this gap 
has closed and there is now almost no sex difference in the prevalence of deliberate solvent abuse 
(SAMHSA, 2007). The above evidence produces a disheartening picture of inhalant abuse.  
According to a recent review of the morbidity and mortality of inhalant abuse, 22 % of individuals 
found dead of an inhalant-related consequence had no history of prior use of the inhalant itself, 
indicating that almost a quarter of new (or, at least, relatively new) users face death (Williams and 
Storck, 2007). In addition, Bennett et al. (2000) suggests that adolescent or pre-adolescent inhalant 
abuse doubles the rate of adulthood binge drinking and significantly increases “hard drug” abuse 
in adult college students, supporting the notion that toluene and other inhalants act as “gateway” 
drugs and that the life-damaging consequences of inhalant abuse do not end when the individual 
stops experimenting with the substance.  
1.3. Methods of Inhalant Abuse 
Inhalation of these chemicals is not complicated and several methods exist for quickly 
achieving high blood/tissue concentrations following self-administration.  Among the many 
methods of abuse is to spray or pour a judicious amount of the substance into a container, such as 
a paper/plastic bag or a balloon, and then to breathe deeply from the container (Bowen, 2011). 
Other methods of abuse include placing objects such as permanent markers, directly under the 
nose and inhaling the contents (“sniffing”), painting the product onto the fingernails and raising 
the fingernails to the nose and/or mouth (“nailing”), inhaling the product directly from the 
container (“sniffing” or “snorting”), soaking cotton balls, cotton swabs or cloth and placing them 
into the nose or mouth (“soaking”), turning a spray can upside down and spraying the aerosolized 
compounds directly into the nose and/or mouth (“spraying”) and “huffing” which is soaking a 
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cloth with a solvent, such as toluene, and inhaling the fumes that arise therein (Flanagan et al., 
1990; Cruz and Bowen, 2008). With each of these procedures, the individual deeply inhales the 
high concentrations of the desired solvent.  The behavioral effects occur very rapidly, usually 
within just a few seconds (Cruz and Bowen, 2008). Evidence suggests that nearly 80% of toluene 
vapor inhaled is absorbed into the bloodstream through the lungs (due to the high lipid solubility 
noted above) with the intoxicating effects continuing for up to 60 min, making inhalant abuse an 
extremely effective form of drug abuse (reviewed in Donald et al., 1991).  
1.4. Effects of Inhalant Abuse 
Like many psychoactive compounds, toluene and other solvents are known to have 
pronounced behavioral effects in both humans and animals (for review, see Bowen et al., 2006; 
Bowen and Cruz, 2014; Cruz and Bowen, 2008).  Individuals who have abused toluene report that 
initial or subjectively low-level exposure to this solvent produces ethanol-like disinhibition and 
euphoria along with the sensation of lightheadedness (Cruz, 2011; Siegel et al., 2009; Cruz and 
Bowen, 2008; Henretig, 1996).  Despite the similarity to ethanol, toluene and other solvents appear 
to be much more potent than ethanol, and therefore require much lower concentrations to produce 
behaviorally meaningful effects (Cruz, 2011).  As the process of inhalant abuse is so heavily reliant 
on personal experimentation, and allowing humans to voluntarily administer toluene in a 
laboratory setting is unethical, it is difficult to estimate an inhaled concentration of a “typical” 
human abuse episode. As such, most dosimetric information about toluene abuse comes from 
animal studies. In a further similarity to ethanol, individuals exposed to higher solvent 
concentrations (in excess of 12,000 ppm) report ataxia, confusion, slurred speech, shallow 
breathing, tiredness, and slowed reflexes (reviewed by Bowen, 2011).  Extremely high 
concentrations of toluene (> 22,000 ppm) have been observed to cause respiratory suppression 
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leading to death, similar to what is observed in ethanol overdose (Moser and Balster, 1985).  In 
addition, solvents have been observed in both animal and human studies to have a variety of 
pseudo-beneficial effects (so-called because the deleterious effects of solvent misuse far outweigh 
any incidental benefits) including anxiolytic, antidepressant and anesthetic effects, making solvent 
misuse a popular and readily available method of “self-medicating” for mood and anxiety disorders 
(Cruz, 2011).   
This higher potency is especially problematic with solvents as they do not have pre-
standardized doses for effective and/or safe use. An individual set upon “huffing” a particular 
commercial product generally has to rely on word of mouth as to the strength of product they are 
about to inhale (e.g., anecdotal rumor suggests that gold spray paint produces a more intense “high” 
than other colors). This lack of standardization for what dose accomplishes what effect, coupled 
with the imprecise methods of administration (e.g., a “bag full” of paint thinner is hardly an exact 
measurement), means that accidental overdoses are alarmingly easy (e.g., “Sudden Sniffing 
Death;” Bowen, 2011).  In fact, acute exposure to solvents is known to cause an increase in the 
sensitivity of the heart to the effects of the so-called “fight or flight” hormones (i.e., adrenaline 
and noradrenaline), meaning that even a single bout of toluene abuse can result in heart failure and 
death (Cruz, 2011).  
1.5. Neurochemical mechanisms of action  
Toluene, like many psychoactive compounds, has wide action in the brain with c-Fos data 
suggesting that toluene administration increases activity in a large number of distinct brain regions, 
including the ventral tegmental area (VTA), nucleus accumbens (NAc), amygdala, caudate 
putamen (CPu), hypothalamus, and cingulate cortex (Perit et al., 2012; Tomaszycki et al.et al., 
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2013). Additionally, inhalation of abuse levels of toluene vapor is known to change brain 
neurotransmitter dynamics, particularly in the dopamine (DA) system.  However, the 
neurochemical mechanisms that underlie toluene intoxication are not yet fully understood (Yavich 
& Zvartau, 1994; Funada et al., 2002; Bowen et al., 1999). For example, Riegel et al. (2007) found 
that directly administering toluene into the VTA resulted in an increase in DA release in the 
nucleus NAc, while Stengard et al. (1994) found that acutely inhaled toluene increased DA levels 
in the striatum CPu. This evidence is corroborated by further research showing that sub-chronic 
injections of toluene (600 mg/kg, i.p.) increased levels of DA present in the CPu and the NAc ex-
vivo and that the increased DA found in the CPu was present for several hours after the last toluene 
treatment (Riegel et al., 2004).  The in-vivo microdialysis technique has seen limited use in a 
repeated measures design, and no use in a chronic abuse paradigm.  However, Beyer et al. (2001) 
demonstrated that repeated exposure to 8000 ppm toluene increases DA levels in the NAc 
following a cocaine challenge. The impact of toluene on the DA system is also supported by 
evidence that toluene may be a D2 receptor agonist. There is evidence that the effect of toluene on 
behavioral activity is at least in part mediated by the D2 receptor, as pretreatment with 5mg/kg 
(i.p.) remoxipride (a D2 antagonist) reduces the locomotor stimulating effects of toluene injections 
(600 -1200 mg/kg i.p.; Riegel and French, 1999).  
However, the evidence for the impact of toluene abuse on the DA system is not necessarily 
clear-cut.  Kondo et al. (1995) found no effect of acutely injected toluene on DA levels in the 
striatum, inferring that toluene does not act upon DA metabolism in the ventral striatum.  Likewise, 
Gerasimov et al. (2002) did not find an effect of acute toluene alone on DA levels in the NAc, 
though they did find a super-additive effect of toluene and cocaine.  These conflicting reports are 
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particularly important, as microdialysis remains a highly utilized technique for categorizing 
neurochemical effects. 
While DA is of primary importance for the abuse potential of inhaled toluene, research has 
also suggested that toluene exerts its effects on other neurotransmitters.  For example, antagonism 
of GABAA receptor with bicuculline has been shown to block the hypothermia induced by acutely 
inhaled toluene (Paez-Martinez et al., 2013).  Likewise, in vitro research has suggested that toluene 
administration enhances GABAA receptor function, reversibly increasing synaptic currents at those 
sites (Beckstead et al., 2000).  Bale et al. (2005) found that repeated in vitro application of toluene 
to neurons increased NMDA current amplitude but decreased the amplitude of GABA-activated 
currents. This pattern of application is similar to what has been observed with ethanol 
administration.  When taken together, these studies implicate GABAA as a potential target for 
toluene’s action in the brain.  However, even here the effect of toluene is far from clear.  O’Leary-
Moore et al. (2007) reported that acutely administered toluene reduced hippocampal GABA levels 
in juvenile rats.  These effects, when taken together, suggest that GABA itself is a promising target 
for research. 
In addition, in vitro evidence suggests that toluene also has an inhibitory action upon the 
glutamate system, specifically NMDA receptors (Bale et al., 2005). The same study demonstrated 
that repeated in vitro exposure to toluene resulted in up-regulation of NMDA sub-receptors N2A 
and N2B, suggesting that the action of toluene upon NMDA is inhibitory at those binding sites. 
However, mice lacking the calcium/calmodulin adenylyl cyclases 1 and 8 (important plasticity-
related second messenger proteins thought to be associated with intracellular actions of NMDA 
receptors) still show increased ambulatory activity in response to acutely administered toluene 
vapor (Conti et al., 2012). This suggests that calcium-related adenylyl cyclases (and by extension, 
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NMDA) function is not implicated in toluene-induced locomotion. Likewise, acute and repeated 
administration of toluene appears to have anticonvulsant properties such that mice that have been 
exposed to toluene are resistant to NMDA-induced seizures (Cruz, et al., 2003). This further 
suggests that toluene has NMDA antagonist properties. 
In vivo microdialysis is a sampling method where extracellular neurotransmitter levels can 
be examined. Several studies have attempted to simultaneously use in vivo microdialysis during 
their toluene abuse models (e.g., Riegel et al, 2007; Gerasimov et al, 2002; Stengard et al, 1993; 
Stengard et al, 1994). In addition, an established technique for in vivo microdialysis is infusing 
high concentration of potassium to chemically induce action potentials via depolarization of the 
cell membrane (e.g., Casanova et al., 2013; Fuentealba et al., 2010). This chemical induction of 
action potentials can have a super-additive effect when paired with drugs of abuse (as is seen in 
Casanova et al., 2013). Infusing a specific brain region with a compound through the microdialysis 
probe is referred to as “reverse-dialysis,” and relies upon the principle that the drug goes down its 
concentration gradient, moving in the direction from high to low concentration from the probe to 
the brain (e.g.,  Farrar et al., 2011; Mabrouk et al., 2013). Additionally, reverse dialysis can be 
used to locally administer a receptor antagonist to a specific brain region without the need for a 
separate infusion or the cessation of sample collection (Mabrouk et al., 2013). 
A review of the current research has identified a need for additional investigation into the 
neurochemical systems involved with toluene abuse, specifically changes to DA and GABA levels 
following toluene intoxication. While evidence exists that toluene acts upon both DA and GABA, 
these findings are conflicted, and therefore require further investigation. Additionally, the effect 
of toluene inhalation on the DA and GABA relationship has not been examined and doing so would 
provide further information about the actions of toluene upon the brain as a whole. This is 
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especially important in the CPu, where DA and GABA comprise two of the primary 
neurotransmitters. Understanding not only the impact of toluene inhalation on DA in the CPu, but 
the role of toluene’s action on GABA in this region would be highly instructive regarding toluene’s 
effects on both drug-seeking behavior and increased locomotor activity.  Based on the above 
research, it is logical to assume that inhalation of abuse levels of toluene vapor alters brain 
neurotransmitter dynamics (specifically DA), which in turn has implications both for cross-
sensitization and susceptibility to drug abuse after repeated exposure.  
Therefore, the purpose of this thesis was threefold. First, I aimed to establish a mouse 
model for in vivo microdialysis following exposure to volatilized solvents.  This would allow for 
the eventual use of techniques and methods specific to mouse models, including the use of genetic 
models to achieve greater target specificity. Second, I aimed to use this model to examine the 
relationship between acutely inhaled toluene and DA levels in the CPu. Finally, I sought to explore 
the relationship between toluene’s action on GABA and DA in the mouse CPu.  
1.6. Hypotheses 
The hypotheses for this study were as follows:  First, acutely administered toluene would 
alter locomotor levels in a dose-dependent manner with 4000 ppm increasing overall activity and 
8000 ppm depressing activity. Acutely inhaled toluene would also increase DA levels present in 
the CPu, indicating the importance of the CPu in the behavioral actions of toluene and 
identifying the CPu as a target for further neurochemical investigation. Second, the acute 
administration of toluene would sensitize the neurons of the CPu to further stimulation such that 
treatment with high-potassium aCSF would increase DA levels, indicating that toluene exposure 
altered cellular sensitivity to external stimulation. Third, the increase in DA levels and locomotor 
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activity observed after exposure to 4000 ppm toluene would be attenuated by pretreatment with 
the GABAA antagonist bicuculline, suggesting that toluene’s action on GABA is linked both to 
toluene’s locomotor-enhancing effects and to toluene’s action on extracellular DA.
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2.0. Chapter Two: Methods 
2.1. Subjects 
 Adult male Swiss Webster mice (N = 26, approximate postnatal day (PND) = 30), were 
used for this experiment. The mice were purchased from Harlan Breeding Laboratories (Portage, 
MI, USA).  The Institutional Animal Care and Use Committee at Wayne State University approved 
all animal procedures and behavioral experiments which were in accordance with the NIH “Guide 
for the Care and Use of Laboratory Animals: Eighth edition” (National Academy of Sciences 2011, 
revised 2010).  For this study, there were five groups which included three doses of toluene (0 
ppm, 4000 ppm, and 8000 ppm) and two toluene-plus-drug conditions (4000 ppm toluene or air 
control, both with a 30 min pretreatment of 10 μM bicuculline with approximately N = 6 for each 
group). The selected dose of bicuculline was shown by prior research to be effective at locally 
antagonizing GABAa receptors using reverse dialysis (e.g., Farrar et al., 2011 and Mabrouk et al., 
2013).  
Prior to the microdialysis surgery, mice were housed in groups of 4 - 5 in polypropylene 
cages (18 cm x 29 cm x 13 cm) with hardwood chip bedding and steel-wire tops within a certified 
vivarium (Association for Assessment and Accreditation of Laboratory Animal Care; AAALAC) 
at Wayne State University. Mice were allowed ad lib access to food and water (Rodent Lab Diet 
5001) in their home cages. The vivarium was temperature controlled (20 – 22 oC) and kept on a 
standard 12 hour light dark cycle with lights on at 0600 hrs. While in the vivarium, animal welfare 
was monitored by trained veterinary staff. The animals were transported from the vivarium in the 
basement of the Biological Sciences building to the adjacent Chemistry building to undergo 
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surgery, after which they were singly housed. After surgery recovery, the animals were transported 
back to Biological Sciences to undergo behavioral/neurochemical testing.  
2.2. Surgery  
After arrival to the vivarium, the animals were allowed to acclimate for one week before 
undergoing microdialysis surgery. Prior to surgery, all surfaces of the surgical area were cleaned 
and disinfected and the surgeon thoroughly scrubbed their hands prior to putting on sterile surgery 
garments (i.e., gloves, cap, mask, and lab coat). Prior to surgery, all instruments were sterilized 
using an autoclave or sterilized with a disinfectant (in the case of instruments like the drill that 
could not be autoclaved).  
Animals were anesthetized with Isoflurane® until the animal was judged to have lost 
reflexive movement in response to a pinch to the webbing between the toes on the hind limb (“toe 
pinch test”). The animal was then transported from the anesthesia-induction chamber to the 
stereotaxic frame (David Kopf Instruments, Tujunga, CA) where it was placed upon a 
microwavable heating pad covered in paper towels. After the animal was affixed to the stereotaxic 
frame using two non-puncturing ear bars and a mouse palate adapter, tubing was placed on the 
nose of the animal and Isoflurane® and oxygen administration was continued to ensure proper 
anesthesia. The “toe pinch test” was re-administered prior to surgery. To protect the eyes of the 
mouse from dehydration during the surgical procedure, sterile artificial tear lubricant ophthalmic 
ointment was applied to the eyes. The fur covering the skull was removed with a commercial 
electric razor and a local analgesic (Lidocaine®) was applied in a circle around the surgery site. 
The surgical site was disinfected with Betadine and ethanol before the skin was incised to expose 
the skull. Hydrogen peroxide was then applied to the skull with a Q-tip®. This step was both to 
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ensure the removal of the membrane covering the skull and to highlight the Bregma and Lambda 
markings. Using a standard mouse atlas (Paxinos, 2001) the anterior-posterior and medial-lateral 
coordinates of the ventral portion of the striatum, specifically the CPu were located and marked. 
Once completed, a hole was drilled through the skull at the marked location. A sterile stainless 
steel guide cannula (CMA/7, 2mm) was then stereotaxically implanted unilaterally (right side) 
according to coordinates extrapolated from the mouse brain atlas. The coordinates (in mm) relative 
to the Bregma suture and the top of the skull were: AP +1, ML -1.6, DV -2.5.  A second hole was 
drilled for a screw support. Dental cement was used to affix the cannula to the skull and hold it in 
place. The dental cement completely covered the exposed skull region so that no sutures or stitches 
were necessary. Each guide cannula was fitted with a dummy cannula that extended the length of 
the guide to keep it clear and free of debris.  The animal was then placed in a heated recovery 
chamber and was monitored until independent locomotion was re-established. The animal was 
then individually housed until the beginning of microdialysis. The animals were allowed to recover 
for at least 72 hours before testing.   
2.3. In vivo microdialysis measurements 
Following recovery from surgery, the dummy cannula was removed and replaced with a 
CMA/7 dialysis probe 12 - 24 hours prior to beginning of the dialysis experiment. The cannula 
was perfused overnight with artificial cerebral spinal fluid (aCSF) consisting of 0.4 mM ascorbic 
acid, 126 mM NaCl, 2.5 mM KCl, 1.2 mM MgCl2, 2.4 mM CaCl2, 25 mM NaHCO3, 1.2 mM 
NaH2PO4, 11 mM D-glucose, pH 7.4, according to procedures described previously (see Bosse et 
al., 2011). During data collection, flow rates for the dialysis pump were set to 1.1 μL/min for the 
duration of collection. To measure changes in DA levels, eight 15-min baseline dialysis samples 
were collected before toluene exposure began, two 15-min fractions were collected during toluene 
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exposure, and four subsequent 15-min samples were collected immediately following toluene 
inhalation. Following the conclusion of this recovery period, aCSF was switched to an aCSF 
solution containing 60 mM potassium for one fraction (15 min) before being returned to normal 
aCSF for four more fractions to monitor the effect of the high-potassium stimulation. During the 
receptor antagonist study, bicuculline was mixed into aCSF at a 10 μM concentration and was 
perfused directly into the CPu for the 30 min prior to toluene administration to locally antagonize 
GABAA receptors within the CPu. After the 30 min of bicuculline-aCSF administration, regular 
aCSF was used for toluene administration and recovery. For a schematic of the exposure paradigm, 
see Fig. 1. 
 
 
 
Figure 1: Schematic outline of the exposure paradigm. After collecting 8 baseline fractions, 
animals were exposed to 30 min of toluene, followed by 1 hour of recovery. Then, animals were 
exposed to high-potassium aCSF for 15 min before being observed for 1 hour. 
2.4. Test Chemicals and Exposures 
Testing consisted of a single 30 min exposure to toluene vapor, a duration chosen to be 
consistent with prior research by this lab (Tomaszycki et al., 2013; Bowen and Hannigan, 2013). 
The two doses chosen for this experiment, 4000 ppm and 8000 ppm, constitute moderate to high 
doses of toluene that have been shown in previous studies to be behaviorally active doses (Conti 
et al., 2012). The 10 μM dose of bicuculline used may appear high, but the diffusion of bicuculline 
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out of the semi-permeable membrane is very low (< 20% of the concentration administered), 
suggesting that the administered dose must be high to ensure a meaningful concentration reaches 
the brain. The dose used was based on prior published work with bicuculline administered via 
reverse dialysis (e.g. Zackheim and Abercrombie, 2005; Whitehead, et al., 2001). 
2.5. Solvent Exposure and Behavioral Testing 
A dynamic exposure system similar to that described by Bowen and Balster (1996) was 
used for toluene exposure (see Fig. 2). The chamber consists of a 37.8 L glass rectangular tank 
(51cm x 28cm x 12cm, 1428cm2 floor area) fitted with a Plexiglas® lid into which toluene was 
delivered in the airflow. The lid was equipped with 1.2 cm access ports located at opposite ends 
which allowed for delivery of toluene vapor as well as the collection of dialysis samples. The 
mouse was restricted to a 30.4 cm x 20.32 cm section of the chamber through the insertion of two 
Plexiglas® walls. The stand for the microdialysis swivel was fixed to one of the Plexiglas walls 
(affixed approximately 2.5 cm from the back wall of the chamber). This allowed the injection and 
collection tubes to exit the chamber through one of the portholes. The second Plexiglas® wall 
(affixed approximately 15.2 cm from the back wall) was perforated with 12 equally spaced 2.5 cm 
diameter holes to allow airflow to pass unobstructed throughout the chamber. The porthole through 
which toluene vapor was administered was located 7.6 cm from this second wall. Vapor generation 
occurred by initially directing air flow through a bubbler that was immersed in a 500-ml solvent 
bath contained in a 1-L round-bottom flask. Air saturated with vapor exited the bath and was mixed 
with filtered laboratory (fresh) air that was then delivered to the exposure chamber for 30 min (see 
Fig. 1). Flow rates through the exposure chambers were maintained at 10 L/min and toluene 
concentration was determined on line using a single wavelength monitoring infrared (IR) 
spectrometer (Miran 1A, Foxboro Analytical, North Haven, CT). At the end of the exposure 
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period, toluene exposure was discontinued and the toluene tubing was replaced with a suction tube 
to facilitate evacuation of toluene vapor from the chamber. The dynamic exposure system was 
housed under a fume hood, which also served to provide white background noise and isolation 
from the laboratory environment. 
During the exposure period, animals were allowed to freely move around the interior of 
the chamber. Locomotor activity was measured within the dynamic exposure chamber via 3 sets 
of 16-beam infrared (I/R) emitter–detector arrays (Med Associates, St. Albans, VT) mounted on 
Plexiglas bases around the sides of the exposure chambers. Interruptions of I/R beams resulted in 
Figure 2: Schematic representation of the dynamic exposure system. Airflow from the air 
regulator is passed through the air bubbler filled with liquid toluene. The resulting toluene 
vapor is carried to the exposure chamber and mixed with clean air to control concentration and 
flow rate. The infrared beam grid is controlled by a computer interface that allows for real-time 
recording of locomotion.  
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an analog signal being recorded by automated activity software (Open Field Activity Software 
[SOF-811], Med Associates, St. Albans, VT). This system quantified total beam breaks in both the 
vertical and horizontal planes, specifically encoding measures of distance traveled (cm; calculated 
from number of breaks of adjacent beams) and number of rears (see Fig. 2).  This automated 
measure of activity was transformed into 15-min blocks over the duration of the session. 
2.6. Liquid Chromatography 
All collected dialysate samples were stored in a - 80 o C freezer and analyzed within two 
weeks of collection. High performance liquid chromatograph (HPLC; LC-20AD pump; Shimadzu, 
Columbia, MD) was used to analyze samples by manually injecting 10 µL of dialysate samples 
into a 10 µL injection loop. The mobile phase that was used to help separate the analytes was the 
ESA MDTM mobile phase (which consisted of: 75 mM NaH2PO4, 3 mM 1-octanesulfonic acid, 
0.125 mM EDTA, 9 % acetonitrile, and 0.2 - 0.5 % triethylamine; pH = 3.0) and was operated at 
a flow rate of 0.4 mL/min. The analytes were further separated using a C18 column (Luna 100 x 3 
mm, C18, 2.6 μm column; Phenomenex, Torrance, CA). DA was electrochemically detected using 
ESA 5014B microdialysis cell (E1 = -150 mV; E2 = +220 mV; ESA Coulochem III (Thermo-
Fisher, Chelmsford, MA) with an in-line ESA 5020 guard cell (potential of guard cell: + 350 mv) 
positioned before the injection loop. Separation and quantification of the analytes on the HPLC 
system was controlled by LC Solutions Software (Shimadzu, Columbia, MD). The approximate 
retention time of DA was at approximately 7 - 8 min. Integration and quantification of DA peak 
area were performed against known concentrations of DA standards (0, 2.5, 5, and 10 nM).  
2.7. Histological verification of microdialysis probe placement  
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After the conclusion of microdialysis testing, the mice were sacrificed using CO2 narcosis. 
Their brains were then removed and stored in 3.7% formaldehyde solution until histology. During 
histology, brains were transferred to a solution containing 2% Cresyl violent dye and allowed to 
sit for approximately 18 hours. Brains were then removed and rinsed three times with 95% ethanol 
before being placed in a solution of 70% ethanol and water and set on a plate shaker for 3-4 hours 
to wash off excess dye. The solution was changed and replaced and the brains were left in 70% 
ethanol and allowed to shake overnight. The next day, the brains were rinsed again by letting them 
sit in 95% ethanol in water for 30 min followed by 45 min sitting in water. After this, brains were 
fixed in 2% agarose solution to aid in cutting. After the agarose had set, brains were sectioned into 
150 µm coronal slices using a Vibratome (Vibratome, St. Louis, MO) until slices of the striatum 
containing the CPu were obtained. These slices were then examined under a microscope (Olympus 
SZX7) and photomicrographs of the track marks were taken.  
2.8. Data analysis 
Spontaneous locomotor data was converted to a percentage of baseline activity to control 
for increased variability due to the small sample size. Without conversion to percent of baseline, 
individual differences in basal ambulatory distance would have obscured any locomotor trends. 
Additionally, the use of percent of control for the locomotor data allowed for easy comparison 
with the dialysis data. Locomotor data was analyzed with SPSS using a mixed-factorial ANOVA 
for both exposure and recovery, with time bins serving as the repeated measures variable (2 bins 
for exposure and 4 bins for recovery) and dose-condition and bicuculline condition serving as the 
independent variables in both analyses. An alpha level of p<0.05 determined statistical 
significance.  Tukey’s HSD post-hoc contrasts were used to determine the locus of significant 
20 
 
 
 
main effects and interactions. Individual fractions were assessed as single univariate ANOVAs 
with dose and bicuculline condition serving as between-subjects variables. 
Statistical analyses of all neurochemical measurements were also done using SPSS. 
Baseline DA levels were calculated by averaging DA levels found in the 8 baseline fractions. 
Outlier baseline fractions were determined using the criteria Z > 2.5. DA levels during the 
experimental phase were represented as a percent of that baseline average as previously reported 
in Bosse and Mathews (2011) and Mathews et al. (2006). The toluene administration study was 
analyzed with a 2 x 3 x 2 Mixed Design ANOVA for exposure and a 2 x 3 x 4 Mixed Design 
ANOVA for recovery, with dose and bicuculline condition serving as the between subjects 
variables, and the two fractions of toluene exposure or four fractions of recovery serving as the 
within subjects factors. Post-hoc tests were performed using Tukey’s HSD. Extracellular DA 
levels was further analyzed for the two toluene administration fractions with two 2 x 2 ANOVAs 
with dose and bicuculline condition serving as the between-subjects variables. The high potassium 
experiments were analyzed with two separate univariate ANOVAs (both 3 x 2 ANOVAs), one 
each for the 15 min of potassium exposure and the 15 min immediately following exposure. For 
the Mixed ANOVAs analyses, in cases where sphericity was violated, the Huynh-Feldt degrees of 
freedom correction was utilized.  
3.0. Results 
3.1. Dynamic Exposure System 
 For the 4000 ppm condition, the average time until concentration asymptote and 
concentration elimination was approximately 7.5 min (see Fig. 3), while the 8000 ppm condition 
took approximately 7.5 min to asymptote and 9.5 min for elimination. The concentration 
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remained stable for the entire exposure duration, and no meaningful traces of the solvent 
remained in the chamber after testing. 
 
Figure 3: Infrared spectroscopy plot of increasing and decreasing toluene concentrations within 
the dynamic exposure chamber. Each vertical line represents one min. Toluene concentration 
reached the target 4000 ppm or 8000 ppm in approximately 7.5 min and remained constant until 
exposure was discontinued at thirty min. Evacuation of toluene from the chamber took between 
7.5 and 9.5 min, depending on the dose utilized. 
 
3.2. Locomotor activity (or distance travelled) during acute toluene administration 
 During toluene exposure, there was a significant effect of time, F (1, 22) = 8.44, p < 0.05, 
such that as time increased, locomotor activity decreased, irrespective of treatment condition (see 
Fig. 4). While there were no significant time x dose (F = 1.8, p = 0.18), time x bicuculline (F = 
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0.045, p = 0.83), or time x dose x bicuculline interactions (F = 0.087, p = 0.77), there was a 
significant between-subjects effect of toluene dose, F (2, 22) = 3.90, p < 0.05, with animals in 
the 4000 ppm group showing significantly elevated locomotor distances as compared to air 
controls. There was no effect of bicuculline, F (1, 22) = 1.03, p = 0.32, and no dose x bicuculline 
interaction (F = 0.72, p = 0.39). 
 
Figure 4. Locomotor distance traveled (mean ± SEM) during toluene exposure in fifteen min 
bins. T1 denotes the first fifteen min of exposure while T2 denotes the second fifteen min. Data 
is represented as percent of average locomotor distance traveled during the second hour of 
baseline.  
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3.3. Locomotor activity (or distance travelled) during acute toluene recovery 
 During recovery from toluene exposure, there was a significant main effect of time, F 
(1.44, 31.75) = 7.09, p < 0.001, such that as time increased, locomotor activity decreased 
irrespective of treatment condition (see Fig. 5). There was no significant time x dose (F = 1.14, p 
= 0.34), time x bicuculline (F = 1.93, p = 0.13), or time x dose x bicuculline interactions (F = 
1.08, p = 0.32). There was no between-subjects effect of dose, F (1, 22) = 1.58, p = 0.22, or of 
bicuculline, F (1,22) = 2.78, p = 0.109. There was a trending dose x bicuculline interaction, F(1, 
22) = 3.23, p = 0.086, suggesting that the animals in the toluene x bicuculline condition were 
more active during the recovery phase, and remained more active than animals in the toluene, air, 
or air x bicuculline conditions. 
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Figure 5. Locomotor distance traveled (mean ± SEM) after toluene exposure in fifteen min bins 
(R1, R2, etc.). Data is represented as percent of average locomotor distance traveled during the 
second hour of baseline.  
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3.4. Neurochemistry 
3.4.1. Extracellular DA levels during acute toluene administration 
 During toluene administration, no significant main effect of time was observed, F (1, 21) 
= 0.069, p = 0.795.  However, a between-subjects effect of dose was found, F (2, 21) = 7.67, p < 
0.01. Post-hoc analysis revealed that the 8000 ppm dose of toluene significantly elevated 
extracellular DA levels as compared to both air and 4000 ppm doses (p < 0.05; see Fig. 6). 
Finally, there was a trending non-significant time x dose interaction, F (2, 21) = 2.78, p = 0.084, 
with the 8000 ppm condition displaying an upward trend across time, while all other conditions 
remained stable or slightly decreased over time.  
3.4.2. Extracellular DA levels during acute toluene administration following bicuculline 
pretreatment 
As seen in Fig. 6, there was no effect of bicuculline treatment (F = 0.041, p = 0.67).  No 
significant interactions were found for time x bicuculline, or time x bicuculline x dose effects 
(p’s = 0.18 and 0.18, respectively).  Analysis of the two fractions during toluene exposure 
revealed no effect of toluene (p = 0.40) or bicuculline (p = 0.41) during the first 15 min. 
However, during the second fifteen min of exposure there was a significant effect of toluene 
dose, F (1, 17) = 5.79, p < 0.05, with the 4000 ppm conditions having higher extracellular DA, as 
well as a significant effect of bicuculline, F (1, 17) = 22.95, p < 0.001, with the bicuculline 
conditions having higher extracellular DA. There was also a significant toluene dose x 
bicuculline interaction, F (1, 17) = 17.09, p < 0.01, indicating that DA levels for the 4000 ppm x 
bicuculline condition increased during the second 15 min of exposure, while the other three 
conditions remained at baseline levels for all other conditions (see Fig. 6).  
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Figure 6. The effect of acute toluene on extracellular DA (mean ± SEM) during toluene exposure 
in fifteen min bins. Data is represented as percent of baseline DA levels.  
 
3.4.3. Extracellular DA during acute toluene recovery 
 During recovery from toluene exposure, there was no main effect of time, p = 0.645 (see 
Fig. 6).  There were no time x dose, time x bicuculline, or time x dose x bicuculline interaction 
effects (p’s = 0.30, 0.26, and 0.20, respectively).  However, there was a significant between-
subjects effect of toluene dose, F (2, 21) = 8.39, p < 0.01. Post-hoc analysis revealed that the 
8000 ppm dose significantly elevated DA levels as compared to both air control and 4000 ppm 
groups (p < 0.05).  There was no effect of bicuculline or drug x bicuculline interaction (p’s = 
0.55 and 0.22, respectively).  
 
26 
 
 
 
 
Figure 7. Extracellular DA levels in the mouse CPu during recovery from toluene exposure 
(mean ± SEM). Data are represented as a percent of average baseline DA levels in fifteen min 
bins (R1, R2, etc.).  
 
3.4.4. High potassium stimulation following acute toluene administration 
 During the 15 min of high potassium stimulation, there was no main effect of dose (1, 21) 
= 1.91, p = 0.17, or bicuculline, F (1, 21) = 1.12, p = 0.30. However, there was a significant dose 
x bicuculline interaction, F (1, 21) = 7.59, p < 0.05, with animals in the 4000 ppm and 8000 ppm 
groups showing elevated DA levels as compared to animals in the air control group or the two 
bicuculline groups (see Fig. 8).  
 During the fifteen min immediately following the high potassium infusion, there was no 
main effect of dose, F (2, 21) = 2.18, p = 0.14, or bicuculline, F (1, 21) = 0.28, p = 0.60, nor was 
there a dose x bicuculline interaction, F (1, 21) = 2.08, p = .164.  
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Figure 8: The effect of high potassium stimulation on DA levels following toluene exposure. 
Data are represented as percent of extracellular DA levels during baseline in fifteen min bins. 
Bicuculline conditions are checkered for ease of comparison. 
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4.0. Discussion  
The primary purpose of the present research was to develop a novel method for 
characterizing in vivo neurochemical and behavioral characteristics of freely moving mice while 
being exposed to the volatilized solvent toluene.  In this study, a unique dynamic exposure 
system custom-built to enable the concurrent use of in vivo microdialysis and infrared locomotor 
measurement techniques during solvent exposure was employed. I demonstrated toluene dose-
dependent alterations in locomotor activity and extracellular DA levels in free-moving, acutely 
exposed mice. To my knowledge, this is the first such report to examine these variables 
concurrently during active solvent exposure, and the first to examine toluene-induced alterations 
in extracellular DA in mice at all. Furthermore, my work here is the first to utilize reverse-
dialysis infusion as a brain-region specific pretreatment in free-moving mice exposed to toluene. 
Finally, I utilized the GABAA antagonist, bicuculline, to investigate whether or not the actions of 
toluene on the striatal DA system are related to toluene’s action on GABA. 
4.1. Dynamic Exposure System 
 This dynamic exposure system is the first free-moving microdialysis system developed 
for solvent abuse models that does not utilize some sort of restraint on animal movement. 
Additionally, this system is the first apparatus of any kind designed to enable simultaneous 
toluene exposure and dialysate collection in a mouse model. The chamber achieved the requisite 
dose quickly and maintained the dose throughout testing (see Fig 2). Additionally, this system 
represents the first use by this research group of a dynamic chamber for solvent abuse research.  
Compared to the static exposure system utilized by this research group, the dynamic 
exposure system took considerably longer to reach asymptotic concentration. The static system 
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utilized by this group reached asymptotic concentration between 1 and 3 min after initiation of 
exposure (Warren et al, 2000), while the present dynamic system took approximately 7.5 min to 
reach stable levels. Consistent with the findings of Balster et al. (1982), who reported that 4000 
ppm and 8000 ppm in their dynamic exposure system took approximately the same amount of 
time to reach asymptote and to empty after exposure, our dynamic exposure system was very 
similar in the amount of time it took for 4000 ppm and 8000 ppm of toluene to fill the chamber 
(7.5 min for both) with only a slightly longer time to void the chamber (8000 ppm took 2 min 
longer to void than 4000 ppm). The toluene concentration for both conditions was very stable, 
varying by approximately ±5% for both conditions (±200 ppm for 4000 ppm, and ±400 ppm for 
8000 ppm). It is doubtful that the difference in elimination time would impact behavioral results, 
and the difference is an unavoidable product of the higher concentration present in our dynamic 
chamber. In addition, the higher toluene concentration of 8000 ppm appears to have a deleterious 
effect on the rubber tubing used for carrying the vapor to the test chamber.  There was evidence 
of liquid toluene accumulation inside the tubing during exposure, and the tubing had to be 
changed regularly because of signs of discoloration in the tubing, suggesting toluene 
accumulation was damaging the tubes. For these reasons, it appears that 8000 ppm toluene might 
be an upper limit on the concentration curve achievable by this system.  
4.2. Toluene administration dose-dependently altered locomotor behavior in naïve animals 
A key finding in the present experiment was that acute toluene administration resulted in 
qualitatively similar acute behavioral effects in our mice (see Fig. 3) as compared to previous 
reports (Bowen et al., 2010; Conti et al., 2012). That is, in the present experiment, the results 
clearly demonstrated that the new dynamic toluene inhalation exposure system resulted in dose-
dependent biphasic effects on spontaneous locomotor activity in mice. At the lowest 
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concentration (4000 ppm), toluene increased locomotor activity during the first fifteen min of 
exposure (see Fig. 4). However, unlike previous reports (Conti et al., 2012; Bowen et al, 2010), 
this activity was not persistent over time, but instead returned to baseline levels during the next 
fifteen min of exposure. In these prior reports, activity for locomotor stimulating doses (2000 
ppm for both studies) increased activity, which remained elevated for the duration of toluene 
exposure (Conti et al., 2012; Bowen et al., 2010).  
At the highest concentration (8000 ppm), locomotor activity was suppressed with animals 
displaying little to no motor activity following the first fifteen min of exposure (T1) for the 
remainder of the exposure and  recovery periods (see Fig. 4 and 5), although functional 
observational battery assessments were not performed. Even after recovery, most animals 
appeared sedated and did not engage in voluntary locomotor activity. During the 8000 ppm 
toluene exposure, there was evidence of myoclonic tail twitching (“straub tail”) in all of the 
animals. While toluene is classically reported to have anticonvulsant properties (Wood et al., 
1984), the dose utilized here was significantly higher than those used in previous reports and 
may be suggestive of toluene’s convulsant properties at higher concentrations. This twitching 
resulted in locomotor beam breaks that accounted for the small amount of activity seen following 
the T1 time block. The initial increase in locomotor activity during T1 is most likely the result of 
the relatively slow rise to asymptote of the dynamic system. As noted above, it took 
approximately half of the first exposure dialysate collection period for the concentration to 
become stable (7.5 min). During that time, the toluene concentration in the chamber was still 
rising. The rate of rise was asymptotic, such that the chamber concentrations spent more time at 
doses approaching 8000 ppm than at lower concentrations.  However, there was still a period of 
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time when the toluene concentrations within the chamber were below 8000 ppm and at a 
locomotor-stimulating level (< 6000 ppm; Bowen and Balster, 1998).  
Because this report represents the first use of this exposure apparatus, the locomotor 
activity results cannot be directly compared to those previously achieved with the static exposure 
chambers used previously (e.g. Bowen et al., 2010). However, the present results are similar to 
previous reports which have demonstrated that acute inhalation of toluene in Swiss Webster mice 
produces a profile of effects that progress from motor excitation at lower concentrations (i.e., 
500–4000 ppm) to motor impairment, sedation, and anesthesia at concentrations above 6000 ppm 
(Bowen and Balster, 1998). Similar increases in motor activity have been found when toluene 
was administered in rats via inhalation (Himnan, 1984) and systemically (Riegel et al., 2003; 
Riegel and French, 1999). It is also important to note that the animals in these experiments were 
placed in the exposure chamber the night before toluene exposure to allow for physical 
habituation to the microdialysis probe. An unintended side-effect of this step could be that the 
animals were able to habituate to the testing chamber itself, resulting in much lower baseline 
locomotor rates. To our knowledge, these findings are the first to report toluene effects on mouse 
locomotor activity in a dynamic system, and the first to explore the administration of toluene 
vapor to animals that have spent the previous night in the exposure chamber. It is possible that 
the different behavioral pattern observed in the 4000 ppm condition is an artifact of habituation 
or a unique feature of this dynamic exposure protocol. If the observed pattern of locomotor 
activity is due to habituation, this might suggest that toluene exposure might be better viewed as 
a locomotion-moderator rather than a locomotion-inducer. Direct experimental investigation is 
necessary to determine the cause of this discrepant result.  
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4.3. The GABA antagonist, bicuculline, enhances the locomotor increasing effects of 
toluene 
The locomotor effects of the GABAA antagonist, bicuculline, on CPu DA levels are 
particularly interesting. To our knowledge, this investigation represents the first use of 
bicuculline pretreatment in a toluene locomotor experiment. As would be expected of a GABA 
antagonist, the bicuculline dose of 10 μM had no effect on locomotor behavior during air control 
exposures (see Figs. 4 and 5). However, when mice were pretreated with bicuculline and then 
exposed to inhaled toluene, an increase in locomotor activity was observed which persisted for 
the duration of both the toluene exposure and recovery phases. The present locomotor results 
argue that toluene’s ability to induce dose-dependent, biphasic alterations in spontaneous 
locomotor activity is likely related to decreased GABA neurotransmission in the CPu, as this 
effect was significantly enhanced following blockade of CPu GABA receptors.  
These results are contrary to the prior work of Beckstead et al. (2000), who found that in 
vitro toluene administration increased GABAA receptor function in rat hippocampal slices. 
However, the current work differs from Beckstead et al. (2000) in several ways.  The present 
study was in vivo and examined extracellular DA, instead of receptor functioning. Extracellular 
levels of DA in the CPu may be moderated by additional mechanisms, including internal cellular 
actions, afferent pathway signaling, and neurotransmission from neurons within the CPu 
(reviewed by Kreitzer and Malenka, 2008). It is distinctly possible that receptor functioning in 
response to drug administration may vary from brain region to brain region due to the influences 
of these outside factors. Next, the present study used mice instead of rats, and there may be 
species-specific differences in CPu DA-GABA dynamics. Finally, in the present study, the 
region of interest was the CPu instead of the hippocampus. The effect of toluene exposure on the 
CPu GABA receptors may well differ from the hippocampus due to the action of presynaptic 
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modulation by other neurons. This current finding is also contrary to Stengard and O’Connor 
(1994), who found that administration of 2000 ppm toluene did not decrease striatal GABA in 
rats. However, it is possible that 2000 ppm toluene, even when given for 2 hours, is not sufficient 
to depress striatal GABA levels. Indeed, the use of quantitative pharmacokinetic modeling 
indicates that 2000 ppm toluene, if inhaled for two hours, resulted in an estimated 31.19 ppm 
blood toluene concentration, which is less than the estimated 50.88 ppm obtained with a half 
hour of 4000 ppm exposure (estimated peak blood concentrations based on formula developed in 
Callan et al., 2014, in revision). This suggests that a higher dose of toluene, even if given for a 
shorter time, would result in a higher concentration of toluene present in the body. It is possible 
that the effect of toluene and GABA receptor function in the CPu is biphasic: excitatory at low 
doses, but inhibitory at high doses. Additionally, the present study used a unilateral 
administration of bicuculline which may have attributed to our result, as total CPu antagonism 
was impossible in the current design. Future studies should investigate the effect of bilateral CPu 
infusion of bicuculline prior to toluene exposure on locomotor behavior.  
4.4. Acute Toluene exposure increases extracellular DA in the mouse CPu 
 Acute toluene administration had a dose-dependent effect of CPu DA levels. While 4000 
ppm of toluene did not significantly elevate DA levels, the highest exposure of 8000 ppm toluene 
significantly increased extracellular DA levels and this persisted throughout exposure and 
recovery. The increase in extracellular DA in the CPu is consistent with findings from other 
toluene doses in rats (Riegel et al., 2004; Stengard et al., 1994). Stengard et al. (1994) 
demonstrated that in rats, two hour exposures of 2000 ppm of toluene increased extracellular DA 
within the striatum. Gospe and Al-Bayati (1994) have also demonstrated that the blood 
concentration of toluene will continue to rise for up to two hours before becoming asymptotic. 
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As such, it is entirely plausible that the difference between the current findings with 4000 ppm 
and those of Stengard et al. (1994) with 2000 ppm is a function of duration of exposure. 
Additionally, although their work was done ex vivo, Riegel et al. (2004) demonstrated that 
repeated injections of toluene increased CPu DA which persisted for several hours. These results 
are consistent with our current findings at 8000 ppm, in which the increase in extracellular DA 
persisted for at least an hour after exposure.  These findings suggest that CPu DA alone is not 
sufficient to alter locomotor activity, as locomotor activity increased in the 4000 ppm condition 
despite DA levels remaining unchanged. Indeed, this effect is similar to Rose et al. (2013), who 
reported that ethanol-induced locomotor activity was not related to differences in striatal DA 
dynamics in two strains of mice. This suggests that increases in locomotor activity during 
toluene exposure may be related to an interaction between DA and GABA providing further 
evidence for the hypothesis that toluene acts as a moderator of basal locomotor activity, rather 
than as an inducer of novel activity.  
 Despite the discrepancies between this report and other published microdialysis studies, 
these findings are noteworthy in several ways. First, the results obtained here represent the first 
time toluene-induced DA effects have been observed in a mouse model. Secondly, these results 
obtained here represents the first time that freely-moving animals have been exposed to toluene 
during microdialysis. The present study indicates that toluene appears to have a dose-dependent 
effect upon CPu DA dynamics in the mouse brain, suggesting that toluene’s effect on the DA 
system may not be uniform between different brain regions, and that the action of toluene at 
neurotransmitter receptors may be dose dependent. Additionally, the CPu is classically thought 
to be important for aspects of planning and executive functioning (Kreitzer and Malenka, 2008), 
and alterations to neurotransmitters within this region provide insight into the impact of acute 
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toluene misuse on these processes. Indeed, the apparent dose-dependent effect of toluene on CPu 
DA might provide an explanation for seemingly transient nature of solvent misuse, as this critical 
region for the planning of drug seeking behavior does not appear to be as strongly impacted by 
toluene inhalation as other brain regions (e.g. the NAc; Riegel et al., 2007).  
4.5. GABA Antagonism increases DA levels during acute toluene exposure 
 This paper represents the first use of bicuculline in a toluene microdialysis study. Prior 
ex-vivo work via fast-scan cyclic voltammetry has suggested that GABAA agonism increases 
striatal DA levels (Avshalumov et al., 2003). These authors proposed a mechanism through 
which GABAergic neurons act upon glutamatergic neurons (specifically, AMPA neurons), 
which in turn have a negative modulatory effect on dopaminergic neurons. However, in the 
current report, GABAA antagonism in conjunction with toluene administration led to a small 
increase in extracellular DA. It is possible that the action of toluene on DA is also mediated by 
glutamatergic neurons, and in the absence of GABAergic stimulation, the excitatory effect of 
glutamate was increased. It is also possible that not all GABAergic neurons in the striatum are 
acting to inhibit AMPA receptor-containing neurons. There may alternative inhibitory pathways 
acting directly on DA (see Fig. 9 ). Inhibition of these pathways by bicuculline may have 
enhanced DA levels. Likewise, it is possible that there are GABAB or GABAC containing 
neurons that are acting on the pathway explored by Avshalumov et al. (2003), and it is possible 
that toluene’s actions at these sub-receptors was sufficient to increase DA levels in the CPu. 
Indeed, there is evidence that suggests that the theory put forward by Avshalumov et al. (2003) 
may not be accurate. In their review on the function of the CPu, Kreitzer and Malenka (2008) 
note that the CPu is almost entirely absent of glutamatergic signaling, which would make the 
mediated mechanism suggested by Avshalumov impossible. This theoretical framework suggests 
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that GABAA receptors within the CPU may have a primarily inhibitory action on DA neurons, 
and antagonism of GABAA would be expected to produce the obtained increase in extracellular 
DA (see Fig. 9). Indeed, the mechanism for this pathway may occur outside the CPu itself. 
Toluene’s action on CPu GABA could have an inhibitory effect on the dis-inhibitory efferent 
GABA pathway from the CPu to the substantia nigra (SNr). This, in turn, would decrease 
efferent DA pathway from the SNr the CPU. Pretreatment with bicuculline blocked internal CPu 
GABA signaling, which stopped toluene’s inhibitory action on the CPu-SNr GABA pathway. 
This resulted in an increase in efferent GABA to the SNr, which acted to dis-inhibit DA release 
in the SNr, which resulted in increased DA release from the SNr to the CPu. In this manner, 
toluene’s mechanism of action upon DA within the CPu, at least at high concentrations of 
toluene, can be viewed as dis-dis-inhibitory. Thus, the current results provide evidence for the 
hypothesis that, while not critical, DA does play a role in toluene-related locomotor activity.  
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Figure 9: Schematic representation of toluene’s action within the CPu. Toluene inhibits CPu 
GABAergic neurons, which in turn increases CPu DA release within the CPu.  
4.6. Acute Toluene Inhalation Increases Sensitivity to High Potassium Stimulation 
 Following acute toluene exposure, high potassium was directly infused into the mouse’s 
CPu. While the overall magnitude of the increase in DA levels following high potassium 
stimulation didn’t differ between groups, the 4000 ppm and 8000 ppm toluene groups had 
elevated DA levels one fraction sooner (15 min) than air controls. Indeed, the 4000 ppm toluene 
exposure group, which had no effect of toluene administration, demonstrated a robust response 
to potassium during the fifteen min of administration, while the animals in the air condition did 
not respond until fifteen min later. This finding differs from what has been observed with 
amphetamine (Casanova et al., 2013) and opioid agonists (Fuentealba et al., 2010) which 
increased the amplitude of the high potassium stimulated DA release in the medial prefrontal 
cortex, but not the speed at which DA release occurred. Our high potassium extracellular DA 
levels suggest cellular sensitization, though the mechanism of this action is unclear and requires 
further investigation. This hypothesis of cellular sensitization fits with the locomotor findings of 
this paper, suggesting that toluene’s actions (both cellular and behavioral) are at least partially 
modulatory in nature. In this experiment, 4000 ppm toluene was not sufficient to raise 
extracellular DA levels. However, 4000 ppm of toluene exposure was sufficient to increase the 
sensitivity of DA neurons to other forms of stimulation. This sensitizing effect is consistent with 
Gerasimov et al. (2002), who found that toluene increased DA levels in the NAc only when 
paired with cocaine stimulation. This sensitization suggests that toluene is simultaneously a 
modest releaser of DA and a positive modulator for cellular sensitivity, though whether or not 
that modulation is mediation or moderation is presently unknown. The effects of bicuculline on 
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toluene-induced locomotor effects and changes to extracellular DA levels suggests that the 
sensitizing actions of toluene appear to be dependent on normal GABAergic functioning. It is 
possible that the cellular sensitization that underlies the increase in stimulated DA release is 
occurring in GABA receptor-containing neurons and antagonism of GABA inhibits the as yet-
unknown mechanism that causes this effect. It is worth noting the seeming discrepancy of the 
toluene + bicuculline group during high potassium stimulation. While the toluene + bicuculline 
group’s stimulated DA levels seem low, the effect is not significant and as such should not be 
over-interpreted.  
4.7. Future Directions 
 This report has created a number of opportunities for future research, both in terms of the 
findings of the project and the avenues of research opened by the creation of this new combined 
method of simultaneously measuring activity and performing microdialysis in freely moving 
mice during solvent inhalation. First, the findings of this study should be validated by replication 
to confirm the validity of this method. Secondly, the exposure window should be varied 
experimentally to determine that the effect of 4000 ppm toluene on DA levels is indeed an 
artifact of exposure timing and not a species-specific difference in toluene sensitivity. Third, our 
findings suggest that the action of toluene on locomotor activity is, in part, mediated by GABA 
activity, and future studies should investigate this by measuring extracellular GABA during 
toluene exposure with and without pretreatment with bicuculline. The effect of bicuculline 
discovered by our present results strongly suggests that a change in extracellular GABA levels 
will occur in the CPu during toluene administration. Fourth, the action of other GABA receptors 
should be explored to provide further insight into the relationship between toluene, GABA, and 
DA. Fifth, the effects of repeated toluene exposure on DA levels in the CPu should be explored. 
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Sixth, this exposure chamber allows for the unique opportunity to selectively apply 
pharmacological mediation to specific brain regions before, during, and after toluene exposure. 
Indeed, future studies should concentrate on the effects of applying sub-receptor specific 
antagonists and agonists to CPu and NAc tissue before toluene administration to observe the 
effects of various receptors on toluene-induced activity. Seventh, as this study represents the first 
freely moving microdialysis model of inhalant abuse in mice, this project sets the stage for future 
work only possible in mouse models. Indeed, future studies should make use of genetically 
altered mouse models, or site-specific genetic knockdowns, to provide further mechanistic 
control of their inhalant studies. Finally, this system can easily be adapted to allow for other 
behavioral assays, including open field, conditioned place preference, marble burying, pain 
sensitivity, and a variety of operant tasks. 
4.8. Conclusions 
I hypothesized (Hypothesis 1) that acutely inhaled toluene would increase DA levels 
present in the CPu. This hypothesis was supported. Acutely administered toluene increased DA 
levels 3 fold in the mouse CPu at the highest toluene dose, and we are the first to demonstrate this 
in mice. The prediction that the above effect would be exacerbated by high-potassium aCSF post-
toluene exposure (Hypothesis 2) was also supported, albeit in a surprising manner. Instead of 
having elevated DA levels compared to controls, the toluene-treated animals displayed a 
sensitization effect with DA levels increasing more quickly than controls. Taken together, these 
results suggest that toluene both increases extracellular DA and acutely alters cellular dynamics to 
increase sensitivity to future stimulation, though the mechanism for this second effect is as yet 
unknown. 
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The final hypothesis, proposing that the increase in DA levels and locomotor activity 
observed would be attenuated by pretreatment with the GABAA antagonist bicuculline, was not 
supported. Instead, pretreatment with bicuculline increased the effect of toluene on both 
locomotor behavior and extracellular DA levels in the CPu, suggesting that the mechanism of 
toluene’s action on the brain may be more complicated than hypothesized. This result is contrary 
to prior published work suggesting that acute toluene either increases or does not affect GABA 
signaling in the CPu, though this is the first such model to measure DA as an outcome of 
GABAA antagonism in conjunction with toluene exposure, and the first in vivo microdialysis 
model of toluene abuse developed in the mouse. As such these discrepant results are in need of 
further validation and examination.  
In conclusion, I have developed a novel approach to inhalant abuse research:  a method 
by which freely moving mice can be exposed to inhalants during microdialysis collection. 
Additionally, this is the first attempt to examine the DA dynamics of toluene in a living mouse 
model, which opens the field for numerous studies that take advantage of the unique capabilities 
of mouse models. Furthermore, toluene may be best viewed as a modulator of behavioral 
activity, rather than as an activity inducer. Finally, the DA dynamics of acute toluene inhalation 
are related to GABAergic functioning, suggesting that CPu DA alone does not explain toluene-
related locomotor behavior. In conclusion, we have made novel contributions to the inhalant 
literature on empirical and methodological grounds, and have raised a substantial number of 
important questions in need of thorough examination. 
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ABSTRACT 
THE EFFECT OF NMDA AND GABA ANTAGONISM ON DOPAMINE RELEASE IN 
THE MOUSE CAUDATE PUTAMEN FOLLOWING ACUTE TOLUENE 
INHALATION: AN IN-VIVO MICRODIALYSIS STUDY 
by 
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Advisor: Dr. Scott E. Bowen 
Major: Psychology (Behavioral and Cognitive Neuroscience) 
Degree: Master of Art 
Toluene is ubiquitous solvent commonly inhaled recreationally. Despite its frequency of 
misuse, there is little understanding of how toluene acts within the brain. To examine this, this 
master’s thesis examined the impact of acutely inhaled toluene on dopamine (DA) release in the 
mouse CPu in vivo using microdialysis techniques. Toluene inhalation produced dose-dependent 
increases in DA levels as well as changes in locomotor activity. These effects were potentiated by 
pre-treatment with the GABAA antagonist bicuculline via reverse microdialysis delivery. These 
results suggest that the DA dynamics of toluene abuse are related to toluene’s previously explored 
effects on the GABA system. It is possible that the action of toluene on GABA in the caudate 
actually inhibits toluene’s action on DA. Another theory is that toluene activates multiple GABA 
receptor sites, and blocking GABAA blocked a primarily inhibitory pathway.
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